• IRS-19 20ml spray nasal

Expiration date: 04/2025

The composition and form of issue:

Nasal spray-100 ml contains active substances: 

the bacterial lysates 43,27 ml

the composition of the bacterial lysates: 

Streptococcus pneumoniae type I, II , III, V, VIII, XII, 1,11 ml

Staphylococcus aureus ss aureus 9,99 ml

Neisseria subflava 2,22 ml

Neisseria perflava of 2.22 ml

Klebsiella pneumoniae ss pneumoniae of 6.66 ml

Moraxella catarrhalis 2,22 ml

Haemophilus influenzae type B 3,33 ml

Acinetobacter calcoaceticus 3,33 ml

Enterococcus faecium 0,83 ml

Enterococcus faecalis 0,83 ml

Streptococcus pyogenes group A of 1.66 ml

Streptococcus dysgalactiae group C of 1.66 ml

Streptococcus group G of 1.66 ml

excipients: glycine — 4.25 g thimerosal sodium — no more than 1.2 mg flavoring on the basis of Nerol (linalol, alpha-terpineol, geraniol, methylanthranilate, lemon, geraniaceae, monotropy ether of diethylene glycol, phenylethyl alcohol) — 12.5 mg purified water to 100 ml 

in vials of 20 ml (60 doses) in a box 1 vial.

Description pharmaceutical form:

Clear, colourless, sometimes yellowish liquid with a faint odor of the flavor based on Nerol.


Complex preparation of bacterial lysates.

Description pharmacological action:

IRS 19 increases the specific and nonspecific immunity. When spraying IRS 19 is formed a fine aerosol that covers the nasal mucosa, which leads to rapid development of the local immune response. Specific protection is locally formed antibodies class of secretory immunoglobulin type A(IgA), preventing the fixation and reproduction of infectious agents in the mucosa. Nonspecific immunotoxic manifests itself in the enhancement of the phagocytic activity of macrophages and increasing the content of lysozyme.


  • prevention of chronic diseases of the upper respiratory tract and bronchi
  • treatment of acute and chronic diseases of the upper respiratory tract and bronchi (rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis), etc.
  • the restoration of local immunity after an influenza and other viral infections
  • preparations for the planned rapid intervention in ENT organs and in the postoperative period.


  • hypersensitivity to drug or its components in history
  • autoimmune diseases.

Application of pregnancy and breast-feeding:

Not recommended during pregnancy (data on potential teratogenic or toxic effects on the fetus are absent).

Side effects:

During the reception, the IRS 19 may experience the following side effects as related and not related to the effect of the drug.

Skin reactions: in rare cases possible hypersensitivity reactions (urticaria, angioedema) and skin eritematosnye and ekzemopodibnymy reaction.

From ENT-organs and respiratory system: rarely — asthma and cough.

In rare cases, early treatment can be observed — increase in body temperature (&ge39 °C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis.

Described isolated cases of occurrence of thrombocytopenic purpura and erythema.

When the above symptoms are advised to seek medical attention.

Drug interactions:

Cases of negative interactions with other drugs is unknown. In the case of the onset of clinical symptoms of a bacterial infection, antibiotics can be prescribed to continued use of IRS 19.

Method of application and dose:

Intranasally, by aerosol administration 1 dose (1 dose = 1 short press of the spray). When spraying of the drug to keep the vial in a vertical position and put your head back.

To prevent adults and children from 3 months of age (2-3 weeks before the expected rise of the morbidity), and 1 dose of the drug in each nostril 2 times a day for 2 weeks.

For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi: adults and children over 3 years of age — 1 dose in each nostril 2-5 times per day children from 3 months to 3 years — 1 dose in each nostril 2 times a day (after prior release from a mucous discharge). Treatment until symptoms of the infection.

To restore the local immunity after an influenza and other respiratory viral infections: adults and children — 1 dose in each nostril 2 times a day for 2 weeks.

In preparation for the planned surgery and in the postoperative period: adults and children — 1 dose in each nostril 2 times a day for 2 weeks (to start a course of treatment is recommended for 1 week before planned surgery).

At the beginning of treatment can have such reactions, such as sneezing and increased nasal discharge. Usually they are of short duration. If these reactions will be severe, you should reduce the frequency of administration of the drug or cancel it.

If you leave preparation for a long time without use, a drop of liquid can evaporate and the resulting crystals clog outlet nozzle. This phenomenon occurs most often when the nozzle is removed and put into packaging the top end down next to the bottle, not pre-rinsing and not drying it. When blockage of the nozzles make several clicks in a row so that the fluid could pass under the action of excess pressure. If that doesn't help, head lowered for a few minutes in warm water.


Cases overdose unknown.


The use of IRS 19 has no effect on psychomotor functions associated with driving a car or managing machines and mechanisms.

Special instructions:

When prescribing on the basis of bacterial lysates with the aim of immune stimulation in patients with asthma may cause asthma attacks. In this case, it is recommended to stop treatment or take drugs of this class in the future.

Precautions when using

Vial spray:

  • keep away from heat above 50 °C and away from direct sunlight
  • do not puncture the bottle
  • don't burn the bottle, even if it is empty.

Storage conditions:

In the upright position.


  • $16.00